Market Cap (In USD)
1.9 Billion
Revenue (In USD)
582.02 Million
Net Income (In USD)
128.85 Million
Avg. Volume
391.63 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 28.14-41.61
- PE
- -
- EPS
- -
- Beta Value
- 0.77
- ISIN
- US4131971040
- CUSIP
- 413197104
- CIK
- 1802665
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jeffrey M. Dayno M.D.
- Employee Count
- -
- Website
- https://www.harmonybiosciences.com
- Ipo Date
- 2020-08-19
- Details
- Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
More Stocks
-
ZIONP
-
LNALNA Santé SA
LNA
-
DUNIYDuni AB (publ)
DUNIY
-
AWTRFAir Water Inc.
AWTRF
-
TRGGFTarachi Gold Corp.
TRGGF
-
SHRIPISTONShriram Pistons & Rings Limited
SHRIPISTON
-
BBL
-
USHAUsha Resources Ltd.
USHA